Published in ISRN Dermatol on April 10, 2011
Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget (2014) 1.00
Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer. Patholog Res Int (2012) 0.85
Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manag Res (2012) 0.84
NGlycolylGM3/VSSP Vaccine in Metastatic Breast Cancer Patients: Results of Phase I/IIa Clinical Trial. Breast Cancer (Auckl) (2012) 0.80
NGcGM3/VSSP vaccine as treatment for melanoma patients. Hum Vaccin Immunother (2013) 0.78
A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells. Glycoconj J (2013) 0.77
Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin. J Biomark (2013) 0.76
Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis. Patholog Res Int (2013) 0.76
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications. Clin Exp Metastasis (2016) 0.75
Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody. Gene Ther (2015) 0.75
Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. BMC Cancer (2014) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A (2003) 3.13
Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem (2004) 2.17
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13
The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem (1998) 2.07
A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A (1999) 2.05
N-Glycolylneuraminic acid in human tumours. Biochimie (2001) 1.55
Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res (2000) 1.53
Role of tumor-associated gangliosides in cancer progression. Biochimie (2003) 1.51
Gangliosides expressed in human breast cancer. Cancer Res (1996) 1.49
O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science (1984) 1.38
Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res (2006) 1.34
An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol (2002) 1.24
Antigen of "serum sickness" type of heterophile antibodies in human sera: indentification as gangliosides with N-glycolylneuraminic acid. Biochem Biophys Res Commun (1977) 1.23
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma (2000) 1.19
Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol (2006) 1.18
Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma (1995) 1.06
Quantitative determination of N-glycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumor-associated sialic acid by gas chromatography-mass spectrometry. Cancer Res (1991) 1.05
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther (2007) 1.05
Gangliosides with O-acetylated sialic acids in tumors of neuroectodermal origin. Neurochem Res (2002) 1.01
Gangliosides of human melanoma: GM2 and tumorigenicity. J Natl Cancer Inst (1987) 1.00
Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling. Cancer Res (2006) 0.99
Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun (1984) 0.94
Freeze-fracture electron microscopy of in vitro reconstructed human epidermis. J Invest Dermatol (1990) 0.93
Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry. Pediatr Dev Pathol (2010) 0.93
Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. Cancer Res (1985) 0.92
Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System. ISRN Gastroenterol (2010) 0.88
Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides. J Biochem (1995) 0.85
Detection of sialic acids and gangliosides with special reference to 9-O-acetylated species in basaliomas and normal human skin. J Invest Dermatol (2001) 0.85
CDW60, which identifies the acetylated form of GD3 gangliosides, is strongly expressed in human basal cell carcinoma. Br J Dermatol (1995) 0.83
Detection of gangliosides as N-glycolylneuraminic acid-specific tumor-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn J Cancer Res (1988) 0.82
Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma. Int Arch Allergy Appl Immunol (1990) 0.82
Analysis of the expression of Hanganutziu-Deicher (HD) antigen in human malignant melanoma. J Dermatol (1992) 0.81
Alteration in keratinocyte ganglioside content in basal cell carcinomas. J Invest Dermatol (1992) 0.80
Immunohistochemical detection of heterophile Hanganutziu-Deicher antigen in human malignant melanoma. Arch Dermatol Res (1990) 0.80
Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions. Jpn J Clin Oncol (1992) 0.78
Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther (2010) 1.27
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther (2007) 1.05
Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res Treat (2005) 1.05
Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther (2008) 0.99
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res (2010) 0.98
Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum Vaccin (2010) 0.96
Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System. ISRN Gastroenterol (2010) 0.88
Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer. Patholog Res Int (2012) 0.85
Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manag Res (2012) 0.84
Immunohistochemical evaluation of H-R3 a novel humanized monoclonal antibody that neutralizes the EGF-receptor. Appl Immunohistochem Mol Morphol (2007) 0.80
NGcGM3/VSSP vaccine as treatment for melanoma patients. Hum Vaccin Immunother (2013) 0.78
Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody. MAbs (2014) 0.78
Light-chain shuffling results in successful phage display selection of functional prokaryotic-expressed antibody fragments to N-glycolyl GM3 ganglioside. J Immunol Methods (2004) 0.76
Phenotypic heterogeneity in the NCI-H125 cell line affects biological activity using the epidermal growth factor receptor as target. Acta Pharm (2012) 0.75
Immunohistochemical recognition of the epidermal growth factor receptor by the h-R3 antibody in the skin of experimental animals. Appl Immunohistochem Mol Morphol (2004) 0.75